CYP2C9 is an important human drug-metabolizing enzyme that is expressed primarily in liver. Recent studies in our laboratory have shown that the nuclear receptor pregnane X receptor (PXR) is important in the transcriptional activation of the CYP2C9 promoter by drugs such as rifampicin and that the essential element is a constitutive androstane receptor (CAR)/ PXR site Ϫ1839 bp upstream of the translation start site. Both CAR and PXR transcriptionally up-regulate the CYP2C9 promoter via these elements. In the present study, we ask whether additional sites in the proximal promoter also play a role in this induction. We identify two proximal hepatic nuclear factor (HNF) 4␣ binding sites at Ϫ152 and Ϫ185 bp of the CYP2C9 promoter, both of which bind HNF4␣ in gel shift assays and transcriptionally up-regulate this promoter in response to HNF4␣ in HepG2 cells. HNF4␣ synergizes with CAR and with PXR in HepG2 cells treated with rifampicin. The synergy only occurs when the CAR/PXR binding site at Ϫ1839 bp is present. Mutation of the two HNF4␣ binding sites differentially prevented up-regulation of CYP2C9 promoter by both CAR as well as HNF4␣, synergy between the two receptors, and essentially abolished induction by rifampicin in HepG2 cells transfected with PXR. These studies strongly support the hypothesis that there is cross talk between distal CAR/PXR sites and HNF4␣ binding sites in the CYP2C9 promoter and that the HNF4␣ sites are required for maximal induction of the CYP2C9 promoter.
transcriptionally up-regulate this promoter in response to HNF4␣ in HepG2 cells. HNF4␣ synergizes with CAR and with PXR in HepG2 cells treated with rifampicin. The synergy only occurs when the CAR/PXR binding site at Ϫ1839 bp is present. Mutation of the two HNF4␣ binding sites differentially prevented up-regulation of CYP2C9 promoter by both CAR as well as HNF4␣, synergy between the two receptors, and essentially abolished induction by rifampicin in HepG2 cells transfected with PXR. These studies strongly support the hypothesis that there is cross talk between distal CAR/PXR sites and HNF4␣ binding sites in the CYP2C9 promoter and that the HNF4␣ sites are required for maximal induction of the CYP2C9 promoter.
CYP2C9, the major member of the CYP2C subfamily in human liver, metabolizes more than 16% of clinically used drugs, including the hypoglycemic agents tolbutamide and glipizide, the anticonvulsant phenytoin, the anticoagulant warfarin, numerous nonsteroidal anti-inflammatory drugs such as flurbiprofen, diclofenac (Goldstein, 2001) , as well as some newly developed drugs such as the antihypertensive losartan and the diuretic torsemide (Goldstein and de Morais, 1994; Goldstein, 2001) . It also metabolizes endogenous compounds such as arachidonic acid. It is well known that the presence of genetic polymorphisms in the CYP2C9 gene results in individual variability in the metabolism of CYP2C9 substrates in humans (Sullivan-Klose et al., 1996; Goldstein, 2001; Blaisdell et al., 2002) .
Another potential source of variation in the metabolism of CYP2C9 substrates is induction by previous exposure to drugs, which may result in tolerance or therapeutic failure. Previous clinical reports have shown that the clearance of typical substrates of CYP2C9 are increased in humans after the administration of certain drugs, such as rifampicin, phenobarbital, and the herbal medicine St. John's Wort (Zilly et al., 1975; Kay et al., 1985; Williamson et al., 1998; Henderson et al., 2002) . In vitro studies in human primary hepatocytes have also demonstrated that CYP2C9 is induced at the level of mRNA, protein, and catalytic activity by drugs such as rifampicin, hyperforin (the active constitute in St. John's Wort), phenobarbital, and the glucocorticoid dexamethasone (Chang et al., 1997; Gerbal-Chaloin et al., 2001; Raucy et al., 2002; Madan et al., 2003; Komoroski et al., 2004) . Promoter studies have revealed two constitutive androstane receptor (CAR)-responsive elements (REs) within the CYP2C9 promoter (at Ϫ2898 and Ϫ1839 bp from the translation start site) and one glucocorticoid-responsive element at Ϫ1697 bp Gerbal-Chaloin et al., 2002; Chen et al., 2004) . These sites bind CARs and pregnane X receptors (PXRs) or glucocorticoid receptors (GRs), respectively, to mediate the induction of CYP2C9 by various drugs including rifampicin, phenobarbital, hyperforin, and dexamethasone.
CYP2C9 is preferentially expressed in the liver and appears to be regulated by various hepatic transcriptional factors such as HNF4␣ and HNF3␥ (Ibeanu and Goldstein, 1995; Jover et al., 2001; Bort et al., 2004) . HNF4␣, one nuclear receptor expressed mainly in the liver, intestine, kidney, and pancreas, activates the transcription of target genes either through its recognition of a direct repeat DR1 motif or its recruitment of chromatin remodeling systems (Sladek and Darnell, 1992; Hu and Perlmutter, 1999) . In liver, HNF4␣ sustains the constitutive expression of a large number of hepatic genes, including cytochrome P450s such as CYP2A6, 2B6, 2D6, 3A, and 7A1, as well as the glucuronyl transferase UGT1A1, certain hepatic transporters, and even regulatory factors such as PXR and HNF1␣ (Watt et al., 2003) . Importantly, HNF4␣ is involved in the transcriptional responses of hepatic genes to endogenous compounds or xenobiotics, such as induction of several major enzymes involved in gluconeogenesis (phosphoenolpyruvate carboxykinase, glucose-6-phosphatase, and liver carnitine palmitoyltransferase I) by glucagon or glucocorticoid (Stafford et al., 2001; Louet et al., 2002; Gautier-Stein et al., 2005) , drug induction of the P450 gene CYP3A (Tirona et al., 2003) , and inhibition of CYP7A1 by rifampicin (Li and Chiang, 2004) . Moreover, inactivation of HNF4␣ results in suppression of PXR and CYP3A expression in fetal hepatocytes (Hayhurst et al., 2001 ) and the hepatic fasting response mediated by peroxisome proliferator-activated receptor ␥ coactivator-1␣ in adult liver (Rhee et al., 2003) .
HNF4␣ has been shown to increase endogenous CYP2C9 mRNA expression when overexpressed in HepG2 cells (Jover et al., 2001) . One putative HNF4␣ binding site has been reported in the CYP2C9 basal promoter region by our laboratory (Ibeanu and Goldstein, 1995) . In the present study, we ask whether HNF4␣ has a role in the transcriptional regulation of CYP2C9. We used reporter assays, mutagenesis, and electrophoretic mobility shift assay (EMSA) to identify and functionally characterize two HNF4␣ sites in the CYP2C9 promoter. We then examined whether these proximal HNF4␣ sites have a role in the regulation of CYP2C9 by CAR and PXR. We show herein that these proximal HNF4␣ binding sites are required for the optimal activation of the CYP2C9 promoter by both CAR and PXR, probably through cross talk between HNF4␣ and CAR/PXR. Importantly, this study shows evidence for cross talk between HNF4␣ and CAR/PXR involving both distal CAR/PXR sites and proximal HNF4␣ elements in the CYP2C9 promoter.
Materials and Methods
Chemicals. Dimethylsulfoxide (DMSO), rifampicin, dexamethasone, and other common reagents were purchased from SigmaAldrich (St. Louis, MO). Rifampicin and dexamethasone were dissolved in DMSO. Cell culture media was purchased from Invitrogen (Carlsbad, CA). Desalted oligonucleotides were purchased from Genosys (Cambridge, UK). Restriction enzymes were purchased from PerkinElmer Life and Analytical Sciences (Boston, MA). All other reagents were of the highest grade available.
Transient Transfection Constructs. The wild-type CYP2C9-3k/pGL3_Basic and three mutants (CYP2C9-3k/-2898m, CYP2C9-3k/-1839m, and CYP2C-3k/dmut) were as described previously (Chen et al., 2004) . All of these constructs start at Ϫ2920 to Ϫ1 upstream the translation start site. For the subsequent promoter deletion constructs, CYP2C9-1874/pGL3_Basic construct (previously named CYP2C9-1.9k/pGL3_Basic) (Chen et al., 2004) was first cleaved by EcoRI, incubated with Klenow Fragment (PerkinElmer Life and Analytical Sciences) to blunt the two ends, and then further digested by EcoRV. Gel-purified large fragments were self-ligated to produce one deletion construct, CYP2C9-1874/⌬-1358/-362. Another deletion construct, CYP2C9-1874/⌬-250/-114, was produced by digesting CYP2C9-1874/pGL3_Basic with AvrII, followed by a gel purification of the large fragment and religation. To produce the chimeric construct CYP2C9/SV40, 1416 bp of the CYP2C9 promoter fragment from plasmid CYP2C9-1874 was digested through double digestion with EcoRV and SacI, then inserted into an SV40 promoter-driven luciferase vector pGL3_Promoter linearized by SacI and SmaI.
pSG5-hPXR was kindly provided by Steve Kliewer (GlaxoSmithKline, Uxbridge, Middlesex, UK) (Kliewer et al., 1998) . (XREM)-3A4-362/ϩ53 was obtained from Brian Goodwin (Goodwin et al., 1999) . pCR3-hGR was described previously (Chen et al., 2004) . The cDNAs of hHNF4␣ were amplified from total RNA of human primary hepatocytes with forward primer, 5Ј-CTCGTCGACATGGACATGGC-CGACTAC 3Ј, and reverse primer, 5Ј GGCTTGCTAGATAACTTC-CTGCTTGGT 3Ј (underlined are the start codon and stop codon, respectively). Gel-purified PCR amplicons were cloned into TOPOpCR2.1 (Invitrogen) and then sequenced. Mutations in PCR products were corrected through quick-change mutagenesis (QuickChange Site-directed mutagenesis; Stratagene, La Jolla, CA). The corrected cDNAs of hHNF4␣ were excised from pCR2.1 by HindIII and XbaI and then inserted into the same restriction enzyme sites of expression vector pCR3.
Cell Culture and Transfection. HepG2 cells were maintained in the Eagle's minimal essential medium supplemented with 10% fetal bovine serum and penicillin-streptomycin at 37°C under 5% CO 2 . Luciferase constructs and receptor constructs (or empty vectors, 100 ng of each) were combined with 2 ng of internal control pRL-TK, then mixed with Effectene transfection reagent (QIAGEN, Valencia, CA) and transfected into HepG2 cells 12 to 24 h after seeding into 24-well plates (1-1.5 ϫ 10 5 cells per well). Twenty-four hours later, medium was replaced, and drugs were added at the appropriate concentrations (0.1% of DMSO, 10 M rifampicin, and 100 nM dexamethasone). Drugs were incubated with the cells for 24 h, followed by dual luciferase assays (Promega, Madison, WI). Firefly luciferase activities were normalized against Renilla luciferase readings of the internal control plasmids to calculate promoter activity.
Site-Directed Mutagenesis. The promoter construct CYP2C9-1874/pGL3_B was used as the template to mutate HPF1 sites in four CYP2C9 promoter mutants: CYP2C9-1874 /-152m1, CYP2C9-1874 /-152m2, CYP2C9-1874 /-185m, and CYP2C9-1874 , respectively, through using QuickChange site-directed mutagenesis kits (Stratagene). The forward primers utilized for mutagenesis are as follows (hexamer half-sites are indicated by bold capital letters, mutated nucleotides are underlined, and deletions are indicated by periods): Ϫ152 mut1, 5Ј CTGTATCAGTCCCTCAAAGTCCTTTC 3Ј; Ϫ152 mut2, 5Ј GTATCAGTGGGTCT.GTCCTTTCAGAAG 3Ј; and Ϫ185 mut, 5Ј GAACAAGACCT.GGACATTTTATTTTTATC 3Ј. CYP2C9 promoter fragments containing expected mutations were verified by DNA sequencing and then subcloned into the fresh pGL3_B vector.
Gel Shift Assays. Human hHNF4␣ was synthesized in vitro using the TNT Quick-Coupled In Vitro Transcription Translation System (Promega), following the manufacturer's protocol. Empty vector pCR3 was also used as the template in parallel synthesis reactions to prepare the control. Nuclear extracts were attained from HepG2 cells following the standard approach in Current Protocols in Molecular Biology. Klenow Fragment (PerkinElmer Life and Analytical Sciences) was employed to incorporate 32 P-dCTP at the 5Ј ends of the double-stranded oligonucleotides. Approximately 50,000 cpm of labeled probe was incubated with 2 l of the synthesized nuclear receptors or approximately 1 g of nuclear extracts in a 10-l binding reaction containing 10 mM Tris-HCl, pH 7.5, 1 mM MgCl 2 , 0.5 mM EDTA, 0.5 mM dithiothreitol, 4% (v/v) glycerol, 50 mM NaCl, and 1 g of nonspecific competitor poly(dI-dC) (Sigma-Aldrich). In parallel reactions, specific cold competitors or specific hHNF4␣ antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) were added to the mixture before the addition of proteins. After 20 min of incubation at room temperature, 9.5 l of the reaction mixture was loaded onto a 5% nondenaturing polyacrylamide gel for electrophoresis in 0.5ϫ Tris borate-EDTA buffer for 2 h at 150 V. The gels were dried and exposed to film. The following are the sequences of the oligonucleotides used as probes, wild-type, or mutated specific cold competitors (hexamer half-sites are indicated by bold capital letters, mutated nucleotides are underlined, and deletions are indicated by periods): Ϫ152 wt, 5Ј-ctagCTGTATCAGTGGGTCAAAGTCCTTTC-3Ј; Ϫ152 mut1, 5Ј CTGTATCAGTCCCTCAAAGTCCTTTC 3Ј; Ϫ152 mut2, 5Ј GTATCAGTGGGTCT. GTCCTTTCAGAAG 3Ј; Ϫ185 wt, 5Ј ctagAACAAGACCAAAGGACATTTTAT 3Ј; Ϫ185 mut, 5Ј GAA-CAAGACCT. GGACATTTTATTTTTATC 3Ј; APF1 wt, 5Ј ctag-GCGCTGGGCAAAGGTCACCTGC 3Ј; and APF1 mut, 5Ј GCGCT-GGCGAAAGGAGACCTGC.
Statistical Analysis. One-way analysis of variance (ANOVA) was followed by bootstrapped multiple comparisons (Westfall and Young, 1993) to compare across constructs or receptors, with the following exceptions. Two-way ANOVA with interaction was utilized to test for synergism. For the first experiment, ANOVA was followed by the Bonferroni test. Supplemental two-sample Student's t tests were used for specific comparisons of two groups in a few cases as noted.
Results
hHNF4␣ Activates the Human CYP2C9 Promoter in HepG2 Cells and Synergizes with the Nuclear Receptor hCAR. To determine whether HNF4␣ activates the CYP2C9 promoter and whether it influences the activation by the nuclear receptor hCAR, expression plasmids containing hCAR and hHNF4␣ were cotransfected into HepG2 cells individually or in combination with a 1874-bp CYP2C9 luciferase promoter construct, the empty vector pGL3_B, or a positive control (XREM)-3A4-362/ϩ53, respectively. As shown in Fig. 1 , both CAR and HNF4␣ significantly up-regulated CYP2C9-1874 (3.5-and 5.4-fold, p Ͻ 0.05), whereas the empty vector was not up-regulated by CAR or HNF4␣. When both nuclear receptors were cotransfected simultaneously activation was synergistic rather than additive (24-rather than 9-fold). This synergy was statistically significant (p Ͻ 0.001). The (XREM)-3A4-362/ϩ53 positive control was activated either by CAR or HNF4␣ as expected, but there was only a weak synergism (p ϭ 0.037) after cotransfection with both receptors.
We then investigated the location and contribution of possible HNF4␣-responsive elements to the synergistic up-regulation of the promoter by CAR and HNF4␣ using various deletion constructs. A chimeric construct CYP2C9/SV40, in which the proximal 1356 bp of the CYP2C9 promoter region was replaced by the SV40 promoter, was activated by CAR (p Ͻ 0.001) but not by HNF4␣, and there was no synergism between CAR and HNF4␣ (Fig. 2) . The CAR activation and HNF4␣ activation were significantly decreased compared with that of the wild-type CYP2C9-1874 promoter. In contrast, when the promoter region from Ϫ1358 to Ϫ362 bp was deleted, the activation of the resulting CYP2C9-1874-⌬-1358/-362 by CAR and HNF4␣ (p Ͻ 0.001) was comparable with that of the full CYP2C9-1874 construct, and the synergy between the two receptors was still observed (p Ͻ 0.001). We finally deleted a very small region (Ϫ250 to Ϫ114 bp) within the CYP2C9-1874 construct containing the putative HPF1 site (Venepally et al., 1992) . CAR activation was decreased from 4-to 2-fold (p Ͻ 0.001), and the HNF4␣ activation and synergistic transactivation by HNF4␣ and CAR were abolished (Fig. 2) . These data clearly suggest the presence of HNF4␣ binding site(s) localized within the basal promoter of CYP2C9 (Ϫ250 to Ϫ114 bp), which are required for the synergistic activation by CAR and HNF4␣.
Identification of Two HNF4␣ Binding Sites That Are Required for Full Activation of CYP2C9 by CAR and HNF4␣. Within this region between Ϫ250 to Ϫ114 bp, one putative HPF1 site has been reported at Ϫ152 bp from the translation start site (Ibeanu and Goldstein, 1995) . To confirm that this putative HPF1 site binds HNF4␣, gel shift assays were first performed with nuclear extracts from HepG2 cells and a 32 P-labeled oligonucleotide probe 2C9-wt containing this sequence (as shown in Fig. 3B, left) . A strong complex was formed, which was essentially eliminated by competition with 5ϫ or 50ϫ excess of wild-type cold competitors 2C9-wt, whereas 50ϫ excess of two cold competitors containing a mutated HPF1 site (shown in Fig. 3A ) competed only weakly for the formation of the complex. Antibody against HNF4␣ retarded the mobility of the complex and produced a supershifted band at the top, further suggesting the existence of HNF4␣ in this complex. Finally, we examined the binding of this probe to in vitro-transcribed HNF4␣. Transcribed products from the expression plasmid pCR3-hHNF4␣ formed a strong complex with the probe, whereas products from the empty pCR3 vector did not produce any bands. All of the wild-type cold competitors 2C9-wt, 2C19-wt, and a positive control HNF4␣ binding oligonucleotide APF1-wt from the human APOCIII gene (Jiang and Sladek, 1997) strongly suppressed the formation of this complex. Mutated oligonucleotides competed less effectively. When antibodies against HNF4␣ were included in the binding reaction, there was marked supershifting of the band (Fig. 3B,  right) .
To verify whether the HPF1 site at Ϫ152 bp plays a functional role in the activation of CYP2C9 by CAR and HNF4␣, mutations were introduced into the CYP2C9-1874 construct, and constructs were examined with transient transfection assays in HepG2 cells (Fig. 4A) . Two different mutations of the Ϫ152 HPF1 site significantly decreased CAR activation (p Ͻ 0.001), but the HNF4␣ activation was only decreased slightly by the Ϫ152 mut1 mutant (p Ͼ 0.05) and the Ϫ152 mut2 mutant (p ϭ 0.03). Synergistic activation by CAR and HNF4␣ was still observed with both mutants (p Ͻ 0.001). These results suggest that although cross talk may occur between the HPF1 site at Ϫ152 bp and the proximal CAR-RE for full CAR activation, other HNF4␣ binding sites may be involved in full activation by HNF4␣ and for the synergistic response between HNF4␣ and CAR.
Using a HPF1 consensus motif (RRRNCAAAGKNCAYY, see Venepally et al., 1992) , we searched the CYP2C9 basal promoter region for additional HNF4␣ binding sites and found another putative site Ϫ185 bp from the translation start codon. To determine whether HNF4␣ also binds this new site, new gel shift assays were performed. A series of complexes were produced by the incubation of nuclear extracts of HepG2 cells and radiolabeled oligonucleotides containing the new site (lane 2 in Fig. 5, left) . The denser complex with lesser mobility indicated by the arrow was eliminated by competition with excess of the wild-type competitors but to a lesser extent by unlabeled mutated Ϫ185mut oligo-nucleotides. Since the mutated cold competitors also competed for the complexes with greater mobility, these may be nonspecific products. Another wild-type HNF4␣ binding oligonucleotide (APF1-wt) essentially eliminated complexes with lower mobility (indicated by arrow) by competition but had less effect on the complexes with greater mobility. Specific HNF4␣ antibodies decreased the intensity of the two complexes with lower mobility (and perhaps the complex with the greatest mobility), whereas a supershifted band appeared at the top (lane 11 in Fig. 5, left) , indicating that HNF4␣ is involved in these complexes. Importantly, when in vitro-synthesized HNF4␣ was incubated with labeled probes (left panel), a single band was observed for HNF4␣ proteins but not for empty pCR3. All wild-type cold competitors including an oligonucleotide from a known HNF4␣ binding site APF1 strongly inhibited the formation of Fig. 2 . The CYP2C9 basal promoter region is required for the activation of the CYP2C9 promoter by HNF4␣ and the synergetic activation by CAR and HNF4␣. A, diagram of promoter constructs for transfection. EcoRI and EcoRV sites were used for a chimeric construct with the SV40 promoter and a 997-bp fragment deletion in the CYP2C9 promoter. AvrII was used to produce a short deletion in the basal promoter of CYP2C9-1874 construct. B, CYP2C9-1874 (wild type and two deleted) and one chimeric promoter construct were transfected into HepG2 cells along with an internal control pRL-TK and nuclear receptor expression plasmids containing hCAR and hHNF4␣. Medium was refreshed on the 2nd day, and luciferase activities were analyzed on the 3rd day. Luciferase activities were normalized to the internal control pRL-TK and fold activation were relative to the value of empty vector cotransfection. Values represent the means of three independent transfections Ϯ S.D. CAR or HNF4␣ significantly up-regulate promoter constructs when compared with the empty vector transfected control at ‫,ء‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01; or ‫,ءءء‬ p Ͻ 0. 001 (ANOVA followed by bootstrapped multiple comparisons). ‡, response of the mutated CYP2C9 promoter construct to HNF4␣ or CAR is less than that of the wild-type construct at ‡, p Ͻ 0.05; ‡ ‡, p Ͻ 0.01; or ‡ ‡ ‡, p Ͻ 0.001. † † †, synergistic rather than additive response to HNF4␣ and hCAR at p Ͻ 0.001 (ANOVA with interaction).
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this complex, whereas two mutated oligonucleotides did not. Antibodies against HNF4␣ effectively abolished this complex, providing further support that the Ϫ185 HPF1 site is a HNF4␣ binding site (Fig. 5, right) .
Mutagenesis of both the new Ϫ185 HPF1 site and the Ϫ152 HPF1 site was performed singly or together in CYP2C9-1874 to functionally evaluate their roles in transactivation of CYP2C9 promoter by CAR and HNF4␣ (Fig. 6A) . As shown in Fig. 6B , the Ϫ185 HPF1 mutation decreased CAR activation from 4.5-fold for wild-type construct to 2.9-fold (p Ͻ 0.001), but this change was smaller than that produced by the Ϫ152 HPF1 mutation (to 1.8-fold, p Ͻ 0.001). However, the decrease in HNF4␣ activation produced by the Ϫ185 mutant (from 8.6-fold for wild-type to 1.8-fold, p Ͻ 0.001) was greater than that of the Ϫ152 mutant (from 8.6-to 3.4-fold, p Ͻ 0.001). The synergistic activation by CAR and HNF4␣ of the Ϫ152 HPF1 mutant (p Ͻ 0.001) was almost comparable with that of the wild-type construct, but the synergism was dramatically decreased for the Ϫ185 HPF1 mutant. When both sites were mutated, activation by CAR and HNF4␣ and their synergistic effects were essentially abolished, clearly showing a cooperative contribution of both HPF1 sites to CAR activation of the CYP2C9 promoter.
Two HPF1 Sites Are Required for PXR-Mediated Rifampicin But Not hGR-Mediated Dexamethasone Induction of CYP2C9 in HepG2.
Earlier studies have shown that the CAR-REs of CYP2C9 also interact with hPXR, which mediates induction of CYP2C9 by rifampicin (Gerbal-Chaloin et al., 2002; Chen et al., 2004) . To examine whether the two HNF4␣ binding sites of the basal CYP2C9 promoter region are also involved in the activation of the induction of the CYP2C9 gene by PXR and rifampicin and activation by PXR, we performed cotransfection assays in HepG2 cells with CYP2C9 promoter constructs and nuclear receptor expression plasmids for PXR and HNF4␣. HNF4␣ appeared to be very important in the induction of CYP2C9-1874 construct by rifampicin and PXR (Fig. 7A ). PXR and HNF4␣ activated this construct (1.6-and 3.8-fold, respectively) when transfected into cells individually, and an additive 6-activation fold was seen when cells were cotransfected with both receptors. Rifampicin caused 3-fold induction in cells cotransfected with PXR (p Ͻ 0.001). When HNF4␣ and PXR were coexpressed in rifampicin-treated HepG2 cells, activation was synergistic (p Ͻ 0.001) rather than additive (21-fold). Mutation of the Ϫ152 HNF4␣ site significantly decreased rifampicin induction of the CYP2C9 promoter construct (p Ͻ 0.001) in cells 
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cotransfected with PXR (from 3-to 1.5-fold) but did not prevent the synergistic response with HNF4␣. Mutation of the Ϫ185 HNF4␣ site did not decrease the PXR-mediated induction by rifampicin but essentially abolished HNF4␣ activation in DMSO-treated cells as well as the synergistic response to HNF4␣ and PXR in cells treated with rifampicin. A double mutation of both HNF4␣ sites almost completely eliminated activation by PXR or HNF4␣ and almost abolished the induction by rifampicin. These data indicate that HNF4␣ and two proximate HNF4␣ sites are involved in the activation of the CYP2C9 promoter by CAR and the optimum induction of CYP2C9 by rifampicin via PXR. HNF4␣ thus synergizes with both CAR and PXR.
Due to the location of both HNF4␣ binding sites in the very basal promoter region, it seemed possible that the mutations of the two HNF4␣ binding sites could exert an effect on basal promoter structure, which affects CAR and PXR activation indirectly. In this case, these mutations should presumably affect other drug responses nonspecifically, such as the activation by dexamethasone, which acts through interaction of a glucocorticoid receptor with a glucocorticoid-responsive element at Ϫ1697 bp. To investigate this possibility, the effects of single and double mutations of the two HNF4␣ binding sites on dexamethasone induction were examined. Although CYP2C9-1874 was strongly activated by dexamethasone (60-fold), the Ϫ152 mutation did not affect this response. The construct with the Ϫ185 mutation and the double mutation exhibited comparable or even slightly higher induction (90-fold) compared with the DMSO vehicle (Fig. 7B) . In summary, it appears that the HNF4␣ site mutants do not alter the CYP2C9 basal promoter structure nonspecifically, and the cooperativity of HNF4␣ and its two binding sites appears to be specific for activation of the CYP2C9 promoter by PXR and CAR.
The Synergistic Activation of the CYP2C9 Promoter by CAR and HNF4␣ Requires an Intact CAR/PXR-RE. CAR and PXR have been shown to activate the CYP2C9 promoter acting through two CAR/PXR-REs located at Ϫ2898 and Ϫ1839 bp upstream of the translation start site, respectively Gerbal-Chaloin et al., 2002; Chen et al., 2004) . The proximal site has been shown to be essential for CAR activation and PXR-mediated induction. To determine whether these elements were required for the synergistic activation of CYP2C9 promoter by CAR and HNF4␣, CAR and HNF4␣ were transiently transfected into HepG2 cells along with the wild-type CYP2C9-3k promoter construct and mutants in which the two CAR/PXR-REs were mutated either individually or in combination (Fig. 8A) . Results shown in Fig. 8B revealed that all constructs could be significantly activated by HNF4␣ (p Ͻ 0.001), although mutation of the proximal CAR/PXR-RE decreased HNF4␣ activation by ϳ50% (p Ͻ 0.01), again suggesting possible cross talk between the CAR/PXR-RE and the HNF4␣-responsive element(s). Moreover, mutation of the proximal CAR/ PXR-RE at Ϫ1839 bp, either alone or together with the mutation of the distal CAR-RE at Ϫ2898 bp, prevented the synergy between CAR and HNF4␣ indicating that the proximal CAR site is necessary for the synergy between CAR and HNF4␣.
Discussion
The present study identifies two proximal HNF4␣ binding sites that mediate transactivation of the CYP2C9 promoter. These sites are located Ϫ185 and Ϫ152 bp from the translation start site, respectively. HNF4␣ and CAR synergistically activated the CYP2C9 promoter. A distal drug-responsive element CAR/PXR-RE at Ϫ1839/Ϫ1824 bp and these two HNF4␣ binding sites were necessary for maximum activation by CAR as well as PXR-mediated drug induction by rifampicin. HNF4␣ was previously shown to transactivate the basal promoter of CYP2C9 (Ibeanu and Goldstein, 1995; Jover et al., 2001 ) in HepG2 cells, and a putative HNF4␣ binding site was identified at Ϫ152 bp. However, our present studies showed that mutation of this site produced only a 50% decrease in HNF4␣ activation, which was considerably less than might be expected if this were the principle HNF4␣ binding site. Moreover, this site did not appear important for the synergy between HNF4␣ and CAR.
In the present study, we identify and an additional DR1 site at Ϫ185 bp, which plays an essential role in HNF4␣ activation of the CYP2C9 promoter. Mutation of the Ϫ185 site abolished most of the HNF4␣ activation of the CYP2C9 promoter in HepG2 cells and was more important in the synergy between CAR and HNF4␣. Mutation of both HPF1 sites was necessary to completely abolish activation of CYP2C9 by HNF4␣. These data show that the two HNF4␣ binding sites function differently but collaboratively to pro- Fig. 4 . Mutation of the HPF1 site at Ϫ152 bp decreases but does not abolish transactivation of the CYP2C9 promoter by CAR or HNF4␣ and does not effect the synergistic activation by CAR and HNF4␣. A, mutations of the Ϫ152 HPF1 site of CYP2C9. Mutated nucleotides are as underlined. B, HepG2 cells were transfected with wild-type CYP2C9-1874 promoter constructs, two mutants, or the positive (XREM)-3A4-362/ ϩ53 control, respectively. Expression plasmids for hCAR or hHNF4␣ were cotransfected either alone or in combination. Luciferase activity was measured on the 3rd day and normalized to the internal control pRL-TK to calculate promoter activities. -Fold activation was based on the value of empty vector cotransfection. Values represent the means Ϯ S.D. of three independent transfections. ‫,ء‬ significantly greater than empty vector control at ‫,ء‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01; or ‫,ءءء‬ p Ͻ 0.001. ‡, response of the mutated CYP2C9 promoter construct to HNF4␣ or CAR is less than that of the wild-type construct at ‡, p Ͻ 0.05; ‡ ‡, p Ͻ 0.01; or ‡ ‡ ‡, p Ͻ 0.001 (ANOVA followed by bootstrapped multiple comparisons). † † †, response to HNF4␣ and hCAR is synergistic rather than additive at p Ͻ 0.001 (two-way ANOVA with interaction).
Fig. 6.
Comparative effects of mutation of both HPF1 sites at Ϫ152 and/or Ϫ185 bp on transactivation of CYP2C9 promoter by CAR or hHNF4␣ and the synergetic activation from CAR and hHNF4␣. A, diagram of constructs used in transfection assay. B, HepG2 cells were transfected by the wild type and deleted CYP2C9-1874 promoter constructs and three mutants, respectively. Expression plasmids for hCAR or hHNF4␣ were cotransfected in parallel either alone or in combination. Luciferase activity was measured on the 3rd day and normalized to the internal control pRL-TK to calculate promoter activities. -Fold activation was based on the value of empty vector cotransfections. Values represent the means Ϯ S.D. of three independent transfections. ‫,ء‬ significant up-regulation of promoter constructs at ‫,ء‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01; or ‫,ءءء‬ p Ͻ 0.001 compared with the empty vector-transfected control (ANOVA followed by bootstrapped multiple comparisons). ‡, response of the mutated CYP2C9 promoter construct to HNF4␣ or CAR is less than that of the wild-type construct at ‡, p Ͻ 0.05; ‡ ‡, p Ͻ 0.01; or ‡ ‡ ‡, p Ͻ 0.001. † † †, synergistic rather than additive response to HNF4␣ and hCAR at p Ͻ 0.001 (ANOVA with interaction). Our studies also indicate that HNF4␣ appears to play a role in rifampicin induction of CYP2C9. These observations add CYP2C9 to the list of hepatic genes, such as phosphoenolpyruvate carboxykinase, CYP3A, and CYP7A1 (Rhee et al., 2003; Tirona et al., 2003; Li and Chiang, 2004) , which need HNF4␣ for maximum stimulatory responses by other nuclear regulatory factors. In these previously described studies, the crucial HNF4␣ sites that permit optimal response are often in the vicinity of the second responsive elements. The adjacent localization of HNF4␣ sites to other regulatory sites may facilitate the stability of DNA binding of transcriptional factors to their responsive elements and protein interactions involved in transactivation to produce maximum activation of certain genes (Stroup and Chiang, 2000; Stafford et al., 2001 ). Li and Chiang (2004) suggested an interaction between HNF4␣ bound to a bile acid-responsive element II, which positively activates CYP7A1 promoter, and PXR bound to a second element approximately 100 bp away, which negatively regulates the promoter after treatment with the ligand rifampicin (Li and Chiang, 2004) . However, in contrast to these previously reported studies, no HNF4␣ binding site was discovered adjacent to either of the two CAR/PXR binding sites in the CYP2C9 promoter. The critical HNF4␣ binding sites of the CYP2C9 promoter were Ͼ1500 bp downstream of the most proximal CAR/PXR binding site, suggesting a more complex mechanism. Recently, Swales et al. (2005) have found that maximal induction of CYP2B6 by CAR involves a synergy between the distal CAR binding site (phenobarbital-responsive enhancer module, at Ϫ1732/ Ϫ1685 bp) and a proximal okadaic acid-responsive element (at Ϫ256/Ϫ233). This synergy involved association of CAR with the proximal okadaic acid-responsive element.
Further studies are underway to investigate the mechanism of the cross talk between CAR/PXR and the HNF4␣ sites of CYP2C9. When CAR and RXR were added along with HNF4␣ in gel shift assays of the Ϫ152 or Ϫ185 HNF4␣ sites, we were unable to demonstrate direct binding of CAR/PXR to either site (data not shown). Moreover, mutation of the essential CAR/PXR site prevented the synergy between CAR and HNF4␣, suggesting this site must be present for the synergy to occur. Possibly, other hepatic protein cofactors or corepressors must be present for an interaction between . ‡ ‡ ‡, induction response of the mutated CYP2C9 promoter construct is less than that of the wild-type construct at p Ͻ 0.001 (ANOVA followed by bootstrapped multiple comparisons). † † †, synergistic induction rather than additive response at p Ͻ 0.001 (ANOVA with interaction). B, hGR-transfected cells were treated with 100 nM dexamethasone. Luciferase activity was measured on the 3rd day and normalized to internal control pRL-TK to calculate promoter activities. ‫,ء‬ effect of dexamethasone on a particular CYP2C9 wild-type or mutated construct (containing a mutated HNF4␣ site) is significantly greater than the vehicle control at ‫,ءءء‬ p Ͻ 0.001 (ANOVA and paired Student's t tests). A, diagram of the promoter constructs used in transfections. X, mutated CAR/PXR RE in the constructs. B, mutations in the proximal CAR/PXR RE abolished the synergy of CAR and HNF4␣ and decreased the activation of the CYP2C9 promoter by HNF4␣. HepG2 cells were transfected with wild-type CYP2C9-3k or the three mutants along with nuclear receptors (either with the empty vector, hHNF4␣ or hCAR alone, or in combination). After 24 h, medium was refreshed and cells grown for another day. Promoter activities were determined by luciferase activity assays performed on the 3rd day. Values represent the means Ϯ S.D. of three independent transfections. ‫,ء‬ significantly greater than empty vector control at ‫,ء‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01; or ‫,ءءء‬ p Ͻ 0.001 (ANOVA followed by bootstrapped multiple comparisons). ‡, response of the mutated CYP2C9 promoter construct to HNF4␣ or CAR is less than that of the wild-type construct at ‡, p Ͻ 0.05; ‡ ‡, p Ͻ 0.01; or ‡ ‡ ‡, p Ͻ 0.001. † † †, response to HNF4␣ and hCAR is synergistic rather than additive at p Ͻ 0.001 (two-way ANOVA with interaction).
HNF4␣ and CAR or PXR. In our studies, coexpression of HNF4␣ and CAR with the CYP2C9 promoter construct yielded synergistic effects in HepG2 cells but not in HeLa cells (data not shown), suggesting the possible involvement of liver-enriched factors, whereas the synergistic activation of (XREM)-3A4-362/ϩ53 by PXR and HNF4␣ was reported to be greater in HeLa cells than in HepG2 cells (Tirona et al., 2003) .
In summary, two proximal HNF4␣ binding sites were identified that mediate transactivation of CYP2C9 promoter and synergize with CAR/PXR. We provide evidence for a possible cooperative cross talk between a distal CAR/PXR site and two proximal HNF4␣ binding sites. HNF4␣ and CAR synergistically activated the CYP2C9 promoter. Both the distal CAR/PXR drug-responsive element at Ϫ1839/1824 and the proximal HNF4␣ binding sites are necessary for the maximum transcriptional activation of the CYP2C9 promoter by CAR and PXR. HNF4␣ sites in the proximal promoter appear to be important in the PXR-mediated induction of CYP2C9 by drugs such as rifampicin as well as its up-regulation by CAR.
